BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca’s portfolio
– Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca – Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021 BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added…
